Skip to main content

Role for the left atrial appendage occlusion device in managing thromboembolic risk in atrial fibrillation

Buy Article:

$48.00 plus tax (Refund Policy)



Only 50% of patients who would benefit from warfarin therapy for atrial fibrillation (AF) receive treatment because of clinical concerns regarding chronic anti‐coagulation. Percutaneous strategies to treat AF, including pulmonary vein isolation with a curative intent or atrioventricular nodal ablation and implantation of a permanent pacemaker for palliative rate control, have not eliminated the need to manage thromboembolic risk. With the development of a percutaneous left atrial appendage (LAA) occlusion device (the WATCHMAN percutaneous left atrial appendage occluder – Atritech Inc., Plymouth, MN, USA) for thromboembolic protection in non‐valvular AF a significant therapeutic option for select patients may be available. We present the first case performed in Australia (24 November 2009) and explore this new methodology.

Document Type: Research Article


Affiliations: Monash Cardiovascular Research Centre, Monash Heart and Monash University Department of Medicine, Southern Health Network, Melbourne, Victoria, Australia

Publication date: March 1, 2012


Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more